What are the trade names and generic names of Gilteritinib?

Gilitinib is a targeted therapy drug that is mainly used to treat certain types of leukemia, especially cases of patients with acute myeloid leukemia (AML) who have FLT3 mutations. It inhibits the proliferation and growth of cancer cells by inhibiting the activity of FLT3 (Fms-like tyrosine kinase3) tyrosine kinase, thereby combating the spread of leukemia cells. Giritinib provides a new treatment option in the treatment of AML, especially when other treatments have failed or relapsed. Its main trade name is XEGATAN/XOSPATA/XOSPATA, which is assigned by the company that manufactures and sells the drug.

The generic name of Gilitinib isGilteritinib. The generic name is the standard name of the drug and is usually used to describe the chemical composition of the drug. Generic names are usually assigned by the International Committee on Nomenclature (INN) and are used for drug labeling worldwide. GilteritinibThe name comes from the drug's chemical structure and mechanism of action. As a targeted drug, Gilteritinib is mainly used to treat leukemia caused by FLT3 gene mutations and works through specific molecular mechanisms. Since Gilteritinib is its main therapeutic ingredient, it is widely used in clinical treatment to help patients control the progression of leukemia.

Gilteritinib (Gilteritinib) treats leukemia by specifically inhibiting the activity of FLT3 tyrosine kinase. FLT3Mutation is one of the common genetic abnormalities in acute myeloid leukemia and is usually related to the proliferation, resistance to apoptosis and migration of tumor cells. Gilteritinib works by inhibiting the kinase activity of FLT3 to prevent the growth of these abnormal leukemia cells, thereby effectively controlling the progression of the disease. Its selective action makes it an important therapeutic option for the treatment of FLT3 mutant leukemias.

The clinical application of giritinib is mainly focused on the treatment of acute myeloid leukemia (AML)FLT3mutant patients. According to the study results, giritinib showed significant efficacy in treating patients with relapsed or refractory AML. After treatment with giritinib, some patients can achieve remission or have their disease significantly controlled. The drug is considered one of the key treatment options for patients with AML who are FLT3 mutation-positive, especially when other treatments such as chemotherapy are ineffective. In addition, clinical trial results of giritinib indicate that a lower risk of side effects is also one of its potential advantages as a leukemia treatment.

Reference materials:https://www.xospata.com/